EXAGEN INC. Contract Liability (Deferred Revenue)
EXAGEN INC. (XGN) had Contract Liability (Deferred Revenue) of $1.49 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-04
- 2026-06-30: Contract with Customer, Liability, Current $1.49M.
- 2026-03-31: Contract with Customer, Liability, Current $681.00K.
- 2025-12-31: Contract with Customer, Liability, Current $675.00K.
- 2025-09-30: Contract with Customer, Liability, Current $641.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $1.49M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $681.00K 10-Q · filed 2026-05-11 |
| 2025-12-31 | $675.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | $641.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.02M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $876.00K 10-Q · filed 2025-05-05 |
| 2024-12-31 | $733.00K 10-K · filed 2026-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |